Compound Profiles
CJC-1295 with DAC
Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation..
Pancragen
KEDW Tetrapeptide | Pancreas Bioregulator
Pancragen works through epigenetic regulation by interacting with chromatin complexes and DNA structures to modulate pancreatic gene expression. Research shows it upregulates critical transcription factors for pancreatic cell maturation including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take CJC-1295 with DAC with Pancragen?
Yes, but with caution. Both CJC-1295 with DAC and Pancragen affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.
Is CJC-1295 with DAC and Pancragen safe together?
Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: insulin disrupting. Monitor accordingly.
What are the interactions between CJC-1295 with DAC and Pancragen?
Both CJC-1295 with DAC and Pancragen affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.
How should I time CJC-1295 with DAC and Pancragen?
CJC-1295 with DAC has a half-life of 6-8 days and Pancragen has a half-life of Not established. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.